ArticlePharmacology research & perspectives2017
Cenerimod, a novel selective S1P
Article in Pharmacology research & perspectives, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Comparative effectiveness and safety of biologics and targeted small-molecule therapies plus stable background therapy in systemic lupus erythematosus: a systematic review and network meta-analysis.Frontiers in immunology · 2026Pooled it
- Multiple-dose pharmacokinetics of cenerimod and the effect of charcoal on its elimination.Journal of clinical pharmacology · 2024Trial
- Lack of Effect of Cenerimod, a Selective S1PInternational journal of molecular sciences · 2022Trial
- Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1PClinical and translational science · 2021Trial
- Modelling pharmacokinetics and pharmacodynamics of the selective S1PBritish journal of clinical pharmacology · 2020Trial
- Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P₁ Receptor Modulator in Healthy Subjects.International journal of molecular sciences · 2017Trial
- Evolving Treatment Strategies for Systemic Lupus Erythematosus in Clinical Practice: A Narrative Review.Cureus · 2024Review
- Animal models of neuropsychiatric systemic lupus erythematosus: deciphering the complexity and guiding therapeutic development.Autoimmunity · 2024Review
- Article
- Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis - a unique therapeutic target in inflammatory bowel disease.Alimentary pharmacology & therapeutics · 2022Review
- In Vitro Characterization of Sphingosine 1-Phosphate Receptor 1 (S1PInternational journal of molecular sciences · 2022Article
- Cenerimod, a selective S1PArthritis research & therapy · 2021Article
- Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis.Drugs · 2021Review
- CXCR7 Antagonism Reduces Acute Lung Injury Pathogenesis.Frontiers in pharmacology · 2021Article
- Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19.International journal of molecular sciences · 2020Review
- Article
- The S1P-S1PR Axis in Neurological Disorders-Insights into Current and Future Therapeutic Perspectives.Cells · 2020Review
- Attenuation of murine sclerodermatous models by the selective S1PScientific reports · 2019Article
- First use of cenerimod, a selective S1PLupus science & medicine · 2019Article
- Cenerimod, a novel selective S1PPharmacology research & perspectives · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sphingosine-1-phosphate receptor 1 (S1P
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.